Trojan horse inspires novel treatment for Parkinson’s disease
In this study, a drug to treat Parkinson s disease is linked to a molecule that enables it to better penetrate the brain.
Parkinson’s disease, characterized by symptoms that include shakiness and difficulty moving, is among the most common neurodegenerative disorders, affecting up to 3% of the world population over 65. A main cause of this disorder is a lack of dopamine, a neurotransmitter involved in motor control, in the substantia nigra pars compacta, a region of the brain that regulates movement. This could be partly attributed to α-synuclein, a protein whose accumulation in dopamine neurons is a hallmark of Parkinson’s and can have toxic effects, causing dopamine neurons to die.
Source：
2021-04-15 17:26
Shijiazhuang Yiling Pharmaceutical, which produces Lianhua Qingwen, a commonly available over-the-counter medicine in China, has seen its sales skyrocket after the traditional Chinese medicine proved effective in the treatment of symptoms related to COVID-19.
The company s revenue grew 50 percent year-on-year in 2020 on the back of surging Lianhua Qingwen sales. Net profit hit 1.22 billion yuan ($184.3 million) last year, up some 101 percent year-on-year, the company said.
TCM has been recognized by many countries worldwide as effective in alleviating some symptoms related to the novel coronavirus, but faces challenges in being exported to markets outside China, according to the company.
E-Mail
Pregnant women remain at increased risk of severe COVID-19, and their risk of being admitted to intensive care or needing invasive ventilation is higher than non-pregnant reproductive aged women with the virus, an ongoing global study has found.
Pregnant women with COVID-19 are at increased risk of severe COVID-19, particularly if they are from ethnic minority backgrounds, or if they have pre-existing conditions like obesity, high blood pressure and diabetes, concludes the research led by the University of Birmingham and World Health Organization (WHO).
Their research, published today (March 11) in the
BMJ, is part of a unique and ongoing living systematic review and meta-analysis of data, which began in April 2020, and follows the researchers first publication in the